Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

Achilles Therapeutics logo

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Key Stats

Today's Range
$1.48
$1.48
50-Day Range
$1.48
$1.48
52-Week Range
$0.63
$1.51
Volume
N/A
Average Volume
744,051 shs
Market Capitalization
$60.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACHL Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
See More Headlines

ACHL Stock Analysis - Frequently Asked Questions

Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41).

Achilles Therapeutics (ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Digital Turbine (APPS), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/14/2024
Today
10/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACHL
CIK
1830749
Fax
N/A
Employees
250
Year Founded
2016

Profitability

EPS (Trailing Twelve Months)
($1.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.67 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-54.45%
Return on Assets
-47.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.04
Quick Ratio
6.04

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.49 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
41,100,000
Free Float
38,889,000
Market Cap
$60.83 million
Optionable
Not Optionable
Beta
1.25

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ACHL) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners